Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B.
A 56-year-old male patient received adefovir dipivoxil (10 mg/day) for chronic hepatitis B resistant to lamivudine. On the fifth week of treatment, the platelet count dropped to 26 x 10(3) mm(-3); anti-platelet antibodies were detectable in serum. The drug was discontinued and the platelet count improved spontaneously. A re-challenge with adefovir caused a new episode of thrombocytopenia, again after a five-week treatment period. To date, thrombocytopenia has not been described after adefovir therapy for chronic hepatitis B and seems to be a rare event.
Stornaiuolo
G
G
Unit of Viral Hepatitis, Department of Infectious Diseases, Second University of Naples, Via Cotugno 1, 80135 Naples, Italy.
Amato
A
A
Gaeta
G B
GB
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000998:Antiviral Agents / Q000009:adverse effects*; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000139:chemically induced*
D000998:Antiviral Agents; D063065:Organophosphonates; D000225:Adenine; C106812:adefovir dipivoxil